Save time and jump to the most important pieces.
Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
10/11/2024 | $70.00 | Equal-Weight | Morgan Stanley | |
10/10/2024 | Buy → Neutral | Seaport Research Partners | ||
10/9/2024 | Peer Perform → Underperform | Wolfe Research | ||
9/23/2024 | Buy → Neutral | Goldman | ||
9/18/2024 | $85.00 → $70.00 | Buy → Hold | Jefferies | |
9/5/2024 | Reduce → Hold | HSBC Securities | ||
9/5/2024 | Buy → Hold | HSBC Securities | ||
9/4/2024 | $26.00 → $41.00 | Hold → Buy | TD Cowen |
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - EMBRAER S.A. (0001355444) (Subject)
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
SÃO PAULO, Nov. 8, 2024 /PRNewswire/ -- EMBRAER S.A. (NYSE:ERJ, B3: EMBR3)) RELEASES ITS THIRD QUARTER 2024 EARNINGS RESULTS. HIGHLIGHTS 2024 Guidance updated: Management believes prior guidance no longer represents evenly balanced opportunities and risks for full-year operations. From an operations point of view, we estimate Commercial Aviation deliveries between 70 and 73 aircraft (down from 72 and 80), and Executive Aviation deliveries between 125 and 135 (unchanged). From a finance point of view, we forecast Revenues in the US$6.0-6.4 billion range (unchanged), Adjusted EBIT margin between 9.0% and 10.0% (up from 6.5% and 7.5%), and Adjusted Free Cash Flow of US$300 million or higher (u
SÃO PAULO, Nov. 5, 2024 /PRNewswire/ -- 3Q24 Highlights Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) of R$ 3.0 billion in the third quarter, 14.9% higher compared to 2Q24. Investments (CAPEX) totaled R$ 1.5 billion in 3Q24, of which R$ 589 million was allocated to Maintenance and R$ 920 million was directed to the Competitiveness of the Business Divisions. Dividend distribution in the amount of R$ 0.30 per share, equivalent to R$ 619,4 million, to be paid based on 3Q24 results. Share buyback program of Gerdau S.A., by the end of October 2024, 39.6 million shares were repurchased, equivalent to R$ 729.4 million. Additional Information Gerdau S.A. informs t
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook Q3 sales from continuing operations grew 9%; constant currency1 sales grew 10% Q3 TAVR sales grew 6%; constant currency1 sales grew 7% TMTT sales grew 73%; PASCAL and EVOQUE commercial launches continue to progress well Q3 EPS of $5.13; adjusted1 EPS of $0.67 Completed sale of Critical Care in Q3, resulting in significant one-time gain Pivotal TAVR and TMTT clinical evidence to be presented next week at TCT Completed enrollment in CLASP IITR trial for PASCAL tricuspid First implants in the JOURNEY pivotal trial with the Edwards J-Valve AR system Rei
EMBRAER S.A.Publicly Held CompanyCNPJ/MF: 07.689.002/0001-89NIRE: 353.003.257-67 SÃO JOSÉ DOS CAMPOS, Brazil, Nov. 8, 2024 /PRNewswire/ -- EMBRAER S.A. ((", Embraer", or ", Company", NYSE:ERJ, B3: EMBR3)), in attention to Resolution CVM nº 44/2021, informs its shareholders and the market in general that it has revised its guidance for 2024. Management believes that the prior guidance disclosed in the Material Fact published on March 18, 2024, no longer represents the best estimate considering the opportunities and risks for full year operations, which is why provides updated projections for 2024: 2024 GUIDANCE (1) PREVIOUS CURRENT Commercial Aviation deliveries 72 - 80 70 a 73 Executive Avi
SÃO PAULO, Nov. 8, 2024 /PRNewswire/ -- EMBRAER S.A. (NYSE:ERJ, B3: EMBR3)) RELEASES ITS THIRD QUARTER 2024 EARNINGS RESULTS. HIGHLIGHTS 2024 Guidance updated: Management believes prior guidance no longer represents evenly balanced opportunities and risks for full-year operations. From an operations point of view, we estimate Commercial Aviation deliveries between 70 and 73 aircraft (down from 72 and 80), and Executive Aviation deliveries between 125 and 135 (unchanged). From a finance point of view, we forecast Revenues in the US$6.0-6.4 billion range (unchanged), Adjusted EBIT margin between 9.0% and 10.0% (up from 6.5% and 7.5%), and Adjusted Free Cash Flow of US$300 million or higher (u
SÃO PAULO, Nov. 5, 2024 /PRNewswire/ -- 3Q24 Highlights Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) of R$ 3.0 billion in the third quarter, 14.9% higher compared to 2Q24. Investments (CAPEX) totaled R$ 1.5 billion in 3Q24, of which R$ 589 million was allocated to Maintenance and R$ 920 million was directed to the Competitiveness of the Business Divisions. Dividend distribution in the amount of R$ 0.30 per share, equivalent to R$ 619,4 million, to be paid based on 3Q24 results. Share buyback program of Gerdau S.A., by the end of October 2024, 39.6 million shares were repurchased, equivalent to R$ 729.4 million. Additional Information Gerdau S.A. informs t
LONDON, July 5, 2023 /PRNewswire/ -- Abra Group Limited, one of the largest and most competitive air transportation enterprises across Latin America, today announced the appointment of David W. Dickson (Dave) to its board of directors as an independent director. Dave will also serve as Chairman of the board's Audit Committee. Dave is an expert in airlines and loyalty programs, with more than 37 years of experience in professional services working in both audit and advisory capacities principally within the air transportation industry. He is a Retired Partner at EY (Ernst & Young LLP), Board Member at Green Africa Airways, and Principal at Global Economics Group. During his EY career Dave wor
IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards' chairman and CEO, Michael A. Mussallem, who recently turned 70, has informed the Board of his decision to retire as CEO in connection with the company's Annual Meeting of Stockholders on May 11, 2023. At the 2023 annual meeting, Mussallem will stand for election as non-executive chairman of Edwards' Board. He will be succeeded as CEO by Bernard Zovighian, currently corporate vice pre
SÃO PAULO, May 16, 2022 /PRNewswire/ -- GOL Linhas Aéreas Inteligentes S.A. (NYSE:GOL) ("GOL" or "Company"), Brazil's largest domestic airline, today announced that its CEO, Paulo Kakinoff, will transition his role to become a member of the Board of Directors. Vice-president of Operations, Celso Ferrer, will be Kakinoff's successor as CEO effective July 1, 2022. "We are delighted to announce Celso Ferrer as CEO of Gol, Kakinoff said. Celso and I have worked side by side for more than seven years. He is an experienced and well-prepared executive; one of the most competent I have known in all my professional career." Serving as CEO since 2012, Kakinoff has led the Company through some of the i
6-K - BRAZILIAN ELECTRIC POWER CO (0001439124) (Filer)
6-K - Vale S.A. (0000917851) (Filer)
6-K - Banco Santander (Brasil) S.A. (0001471055) (Filer)
Morgan Stanley resumed coverage of Edwards Lifesciences with a rating of Equal-Weight and set a new price target of $70.00
Seaport Research Partners downgraded Azul S.A. from Buy to Neutral
Wolfe Research downgraded Vale S.A. from Peer Perform to Underperform
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Citigroup analyst Paul Lejuez downgraded the rating for Lululemon Athletica Inc. (NASDAQ:LULU) from Buy to Neutral, while cutting the price target from $415 to $300. Lululemon shares settled at $272.06 on Wednesday. See how other analysts view this stock. See how other analysts view this stock. Argus Research analyst Kevin Heal downgraded Zions Bancorporation (NASDAQ:ZION) from Buy to Hold. Zions Bancorp shares closed at $50.98 on Wednesday. See how other analysts view this stock. B
Stifel analyst Rick Wise maintains Edwards Lifesciences (NYSE:EW) with a Hold and lowers the price target from $85 to $70.
Oppenheimer analyst Suraj Kalia maintains Edwards Lifesciences (NYSE:EW) with a Outperform and lowers the price target from $100 to $90.